TVTX - Travere Therapeutics, Inc. Stock Price, Fair Value and News

6.55USD+0.21 (+3.31%)Delayed as of 14 May 2024, 02:01 pm ET

Market Summary

USD6.55+0.21

Delayedas of 14 May 2024, 02:01 pm

3.31%

TVTX Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

TVTX Stock Price

View Fullscreen

TVTX RSI Chart

TVTX Valuation

Market Cap

482.7M

Price/Earnings (Trailing)

-3

Price/Sales (Trailing)

3.1

EV/EBITDA

-2.22

Price/Free Cashflow

-1.52

TVTX Price/Sales (Trailing)

TVTX Profitability

EBT Margin

-266.75%

Return on Equity

-217.53%

Return on Assets

-24.28%

Free Cashflow Yield

-65.98%

TVTX Fundamentals

TVTX Revenue

Revenue (TTM)

155.7M

Rev. Growth (Yr)

33.95%

Rev. Growth (Qtr)

-8.18%

TVTX Earnings

Earnings (TTM)

-161.1M

Earnings Growth (Yr)

-57.6%

Earnings Growth (Qtr)

-50.89%

Breaking Down TVTX Revenue

52 Week Range

6.4519.54

(Low)(High)

Last 7 days

-3.2%

Last 30 days

-0.5%

Last 90 days

-20.6%

Trailing 12 Months

-59.8%

How does TVTX drawdown profile look like?

TVTX Financial Health

Current Ratio

2.78

Debt/Equity

5.1

Debt/Cashflow

-0.84

TVTX Investor Care

Shares Dilution (1Y)

2.04%

Diluted EPS (TTM)

-2.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	155.7M	0	0	0
2023	116.9M	120.5M	129.5M	145.2M
2022	126.2M	120.6M	115.1M	109.5M
2021	198.0M	204.1M	221.2M	131.8M
2020	183.5M	187.3M	194.0M	198.3M
2019	165.4M	168.8M	172.4M	175.3M
2018	159.7M	162.3M	162.7M	164.2M
2017	138.2M	143.7M	150.1M	154.9M
2016	111.5M	120.8M	126.7M	133.6M
2015	45.5M	63.9M	83.5M	99.9M
2014	7.3M	14.3M	21.2M	28.2M
2013	6.8M	4.7M	2.5M	360.0K
2012	0	0	0	9.0M
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Travere Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	meckler jeffrey a	acquired	-	-	6,500	-
May 08, 2024	coughlin timothy	acquired	-	-	6,500	-
May 08, 2024	squarer ron	acquired	-	-	6,500	-
May 08, 2024	bruhn suzanne louise	acquired	-	-	6,500	-
May 08, 2024	baynes roy d.	acquired	-	-	6,500	-
May 08, 2024	poole sandra	acquired	-	-	6,500	-
May 08, 2024	lyons gary a	acquired	-	-	6,500	-
May 08, 2024	orwin john a	acquired	-	-	6,500	-
May 08, 2024	williams brinkley ruth	acquired	-	-	6,500	-
Apr 11, 2024	cline christopher r.	sold	-363	6.74	-54.00	chief financial officer

Which funds bought or sold TVTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	VANGUARD GROUP INC	added	13.61	-1,271,590	48,309,500	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	1.25	-66,241	437,010	-%
May 10, 2024	GROUP ONE TRADING, L.P.	new	-	61,179	61,179	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	new	-	368,000	368,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	5.08	-28,832	262,965	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-10.86	-829,504	2,692,020	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	21,364	21,364	-%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	new	-	137,300	137,300	0.01%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-29.00	177	-%
May 10, 2024	Vontobel Holding Ltd.	reduced	-95.55	-2,485,240	98,688	-%

Are Funds Buying or Selling TVTX?

Are funds buying TVTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TVTX

No. of Funds

Unveiling Travere Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 01, 2024	rock springs capital management lp	5.79%	4,411,983	SC 13G
Feb 14, 2024	armistice capital, llc	9.83%	7,384,000	SC 13G/A
Feb 14, 2024	deep track capital, lp	9.99%	7,522,281	SC 13G/A
Feb 14, 2024	macquarie group ltd	6.31%	4,746,144	SC 13G/A
Feb 13, 2024	vanguard group inc	7.34%	5,515,143	SC 13G/A
Feb 12, 2024	janus henderson group plc	0.0%	32,180	SC 13G/A
Feb 09, 2024	morgan stanley	5.5%	4,152,446	SC 13G
Feb 07, 2024	adage capital partners gp, l.l.c.	0.67%	5e+05	SC 13G/A
Jan 25, 2024	state street corp	7.12%	5,352,345	SC 13G/A
Jan 24, 2024	blackrock inc.	10.6%	7,990,020	SC 13G/A

Recent SEC filings of Travere Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading

Peers (Alternatives to Travere Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Travere Therapeutics, Inc. News

Latest updates

Travere Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-8.2%	41,374,000	45,059,000	37,095,000	32,196,000	30,888,000	29,339,000	28,075,000	28,634,000	23,412,000	45,814,500	68,217,000	54,617,000	47,407,000	50,983,000	51,139,000	48,430,000	47,769,000	46,688,000	44,373,000	44,707,000	39,570,000
Costs and Expenses	29.7%	180,611,000	139,292,000	129,680,000	136,147,000	128,257,000	116,041,000	110,679,000	107,160,000	95,393,000	46,445,000	99,928,000	89,932,000	94,956,000	169,533,000	70,574,000	71,541,000	62,836,000	74,855,000	78,810,000	81,236,000	77,798,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	62,836,000	-	78,810,000	81,236,000	77,798,000
S&GA Expenses	11.6%	64,223,000	57,523,500	67,801,000	74,037,000	72,245,000	51,209,500	52,420,000	52,979,000	46,788,000	18,476,000	36,065,000	34,965,000	36,778,000	35,738,000	31,951,000	34,971,000	33,139,000	27,533,000	29,779,000	38,970,000	32,669,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	48,407,000	51,807,000	47,946,000	-	32,349,000	30,790,000	30,249,000	36,366,000	33,220,000	37,934,000	33,443,000
EBITDA Margin	-4.3%	-2.36	-2.26	-2.53	-2.73	-2.67	-2.74	-2.79	-2.18	-1.77	-1.49	-0.99	-1.01	-	-	-	-	-	-	-	-	-
Interest Expenses	-	2,800,000	-	-	-	2,900,000	-	-	-	-	5,570,000	360,000	988,000	409,000	2,486,500	1,123,000	1,316,000	1,976,000	-206,000	2,467,000	2,589,000	2,819,000
Income Taxes	180.9%	191,000	68,000	12,000	65,000	78,000	63,000	145,000	53,000	52,000	4,000	43,000	49,000	313,000	-471,000	23,000	65,000	-18,976,000	32,000	-523,000	69,000	401,000
Earnings Before Taxes	-53.4%	-135,767,000	-88,528,000	-89,229,000	-101,867,000	-96,486,000	-85,573,000	-83,918,000	-79,970,000	-81,694,000	-88,770,000	-35,596,000	-38,963,000	-53,554,000	-122,093,000	-22,526,000	-26,003,000	-18,168,000	-30,227,000	-37,013,000	-38,632,000	-40,576,000
EBT Margin	-3.0%	-2.67	-2.59	-2.88	-3.05	-2.96	-3.03	-2.91	-2.37	-1.94	-1.65	-1.13	-1.16	-	-	-	-	-	-	-	-	-
Net Income	-50.9%	-136,061,000	-90,173,000	150,735,000	-85,630,000	-86,331,000	-65,823,000	-69,656,000	-67,032,000	-75,971,000	-51,573,000	-35,639,000	-39,012,000	-53,867,000	-121,622,000	-22,549,000	-26,068,000	808,000	-30,259,000	-36,490,000	-38,701,000	-40,977,000
Net Income Margin	-34.9%	-1.03	-0.77	-0.67	-2.55	-2.47	-2.54	-2.30	-1.91	-1.60	-1.37	-1.13	-1.16	-	-	-	-	-	-	-	-	-
Free Cashflow	-68.7%	-118,902,000	-70,498,000	-59,764,000	-69,927,000	-81,747,000	-54,670,000	-39,538,000	-36,823,000	-55,451,000	-27,031,000	31,714,000	6,393,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-15.9%	664	789	833	736	808	673	726	779	828	777	775	747	764	607	692	679	573	605	614	648	668
Current Assets	-22.0%	481	617	686	542	605	486	535	587	631	583	579	550	565	410	498	506	407	429	440	457	476
Cash Equivalents	-25.7%	43.00	58.00	144	71.00	161	62.00	151	180	257	166	150	83.00	148	85.00	200	237	67.00	62.00	65.00	76.00	70.00
Inventory	349.6%	42.00	9.00	21.00	19.00	7.00	5.00	7.00	8.00	7.00	7.00	7.00	7.00	7.00	8.00	7.00	6.00	7.00	6.00	5.00	5.00	6.00
Net PPE	-7.2%	7.00	7.00	8.00	9.00	9.00	9.00	10.00	10.00	11.00	11.00	12.00	12.00	12.00	9.00	6.00	3.00	3.00	3.00	3.00	3.00	3.00
Goodwill	0%	1.00	1.00	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	0.2%	589	588	553	620	619	630	626	623	620	475	468	414	401	396	391	360	347	384	368	370	382
Current Liabilities	-2.6%	173	178	139	136	131	142	131	124	119	124	113	97.00	85.00	93.00	75.00	70.00	68.00	95.00	88.00	91.00	104
Long Term Debt	0.1%	378	377	377	376	376	376	375	375	374	227	224	221	218	215	213	210	207	205	202	200	197
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.00
LT Debt, Non Current	-100.0%	-	377	377	376	376	376	375	375	374	227	224	221	218	215	213	210	207	205	202	200	197
Shareholder's Equity	-63.1%	74.00	201	280	116	189	43.00	101	157	208	302	307	332	363	211	301	319	226	221	246	277	286
Retained Earnings	-12.1%	-1,261	-1,125	-1,035	-1,186	-1,100	-1,014	-948	-878	-811	-765	-714	-678	-639	-585	-464	-441	-415	-416	-386	-349	-310
Additional Paid-In Capital	0.7%	1,338	1,328	1,319	1,307	1,292	1,060	1,049	1,037	1,022	1,069	1,022	1,012	1,003	798	765	759	643	637	631	626	597
Shares Outstanding	1.0%	76.00	75.00	75.00	75.00	75.00	64.00	64.00	63.00	63.00	60.00	59.00	61.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,145	-	-	-	1,539	-	-	-	879	-	-	-	1,031	-	-	-	853	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-68.7%	-118,902	-70,473	-59,134	-69,297	-81,117	-54,640	-39,525	-36,806	-55,320	-26,877	32,063	6,496	-26,474	-13,870	6,735	-6,453	-29,155	-4,492	-14,121	-19,109	-20,492
Share Based Compensation	19.8%	9,758	8,144	10,734	11,604	13,764	9,297	8,023	12,637	8,186	7,376	6,986	7,296	7,908	7,001	5,139	5,564	5,910	5,004	4,154	5,676	6,271
Cashflow From Investing	718.9%	104,898	-16,950	133,318	-23,553	-37,039	-36,701	10,079	-39,096	33,165	7,370	32,520	-71,807	-105,706	-125,511	-43,169	67,802	39,551	1,580	4,465	25,230	-11,412
Cashflow From Financing	-523.4%	-525	124	-634	2,266	216,996	551	2,278	831	113,913	33,213	2,414	303	195,753	25,039	-348	108,795	-5,773	95.00	-738	-324	-1,110

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TVTX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 41,374	$ 30,888
Operating expenses:
Cost of goods sold	1,504	4,145
Research and development	49,420	58,162
Selling, general and administrative	64,223	65,950
In-process research and development	65,205	0
Restructuring	259	0
Total operating expenses	180,611	128,257
Operating loss	(139,237)	(97,369)
Other income (expenses), net:
Interest income	6,032	3,646
Interest expense	(2,800)	(2,850)
Other income, net	238	87
Total other income, net	3,470	883
Loss from continuing operations before income tax provision	(135,767)	(96,486)
Income tax provision on continuing operations	(191)	(78)
Loss from continuing operations, net of tax	(135,958)	(96,564)
(Loss) income from discontinued operations, net of tax	(103)	10,233
Net loss	$ (136,061)	$ (86,331)
Basic and diluted:
Net loss from continuing operations, basic (in dollars per share)	$ (1.76)	$ (1.42)
Net loss from continuing operations, diluted (in dollars per share)	(1.76)	(1.42)
Net income from discontinued operations, basic (in dollars per share)	0	0.15
Net income from discontinued operations, diluted (in dollars per share)	0	0.15
Net loss per common share, basic (in dollars per share)	(1.76)	(1.27)
Net loss per common share, diluted (in dollars per share)	$ (1.76)	$ (1.27)
Weighted average common shares outstanding, basic (in shares)	77,136,493	68,174,099
Weighted average common shares outstanding, diluted (in shares)	77,136,493	68,174,099
Comprehensive loss:
Net loss	$ (136,061)	$ (86,331)
Foreign currency translation gain (loss)	629	(566)
Unrealized (loss) gain on marketable debt securities	(1,065)	1,297
Comprehensive loss	(136,497)	(85,600)
Net product sales
Total revenue	39,984	24,178
Operating expenses:
Cost of goods sold	1,504	1,108
License and collaboration revenue
Total revenue	1,390	6,710
Operating expenses:
Cost of goods sold	$ 0	$ 3,037

TVTX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 43,251	$ 58,176
Marketable debt securities, at fair value	397,793	508,675
Accounts receivable, net	22,731	21,179
Inventory	4,532	9,410
Prepaid expenses and other current assets	12,769	19,335
Total current assets	481,076	616,775
Long-term inventory	37,774	31,494
Property and equipment, net	6,943	7,479
Operating lease right of use assets	17,271	18,061
Intangible assets, net	101,182	104,443
Other assets	19,301	10,661
Total assets	663,547	788,913
Current liabilities:
Accounts payable	16,725	41,675
Accrued expenses	139,580	118,991
Deferred revenue, current portion	6,460	7,096
Operating lease liabilities, current portion	5,036	4,909
Other current liabilities	5,428	5,237
Total current liabilities	173,229	177,908
Convertible debt	377,693	377,263
Deferred revenue, less current portion	888	1,835
Operating lease liabilities, less current portion	21,287	22,612
Other non-current liabilities	16,379	8,485
Total liabilities	589,476	588,103
Commitments and Contingencies (See Note 13)
Stockholders' Equity:
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock $0.0001 par value; 200,000,000 shares authorized; 76,108,829, and 75,367,117 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	8	7
Additional paid-in capital	1,337,638	1,327,881
Accumulated deficit	(1,261,683)	(1,125,622)
Accumulated other comprehensive loss	(1,892)	(1,456)
Total stockholders' equity	74,071	200,810
Total liabilities and stockholders' equity	$ 663,547	$ 788,913

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CEO	Dr. Eric M. Dube Ph.D.
WEBSITE	travere.com
INDUSTRY	Biotechnology
EMPLOYEES	462

Travere Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Travere Therapeutics, Inc.? What does TVTX stand for in stocks?

TVTX is the stock ticker symbol of Travere Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Travere Therapeutics, Inc. (TVTX)?

As of Mon May 13 2024, market cap of Travere Therapeutics, Inc. is 482.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers. The fair value of Travere Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Travere Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TVTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Travere Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TVTX is over valued or under valued. Whether Travere Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Travere Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TVTX.

What is Travere Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, TVTX's PE ratio (Price to Earnings) is -3 and Price to Sales (PS) ratio is 3.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TVTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Travere Therapeutics, Inc.'s stock?

In the past 10 years, Travere Therapeutics, Inc. has provided -0.067 (multiply by 100 for percentage) rate of return.